Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Intermittent Claudication - Overview
Intermittent Claudication - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Intermittent Claudication - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Intermittent Claudication - Companies Involved in Therapeutics Development
G. Pohl-Boskamp GmbH & Co KG
Helixmith Co Ltd
ID Pharma Co Ltd
Novartis AG
Pluristem Therapeutics Inc
Intermittent Claudication - Drug Profiles
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emiplacel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Cardiovascular, Dermatology and Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LLG-783 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Intermittent Claudication - Dormant Projects
Intermittent Claudication - Discontinued Products
Intermittent Claudication - Product Development Milestones
Featured News & Press Releases
Nov 12, 2018: New findings from Pluristem’s phase II IC study: PLX-PAD cells significantly improves blood glucose control (HbA1c) and reduce chronic inflammation
Jun 12, 2018: Pluristem Reports Positive Top-Line Results from Its Multitiol Phase II Intermittent Claudication Study
Jun 04, 2018: Pluristem to Announce Top-Line Results of Its Multitiol Phase II Intermittent Claudication Study on June 12, 2018
Nov 29, 2017: Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue
May 11, 2017: CHA Biotech Announces Completion of Koreas Phase II Trial in Intermittent Claudication (IC)
Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multitiol Phase II Trial in Intermittent Claudication
May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem’s Phase II Intermittent Claudication Study
Jul 08, 2013: Pluristem’s South Korean Partner Files IND With Korean FDA for PLX Cells
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Intermittent Claudication, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Intermittent Claudication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Intermittent Claudication - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H2 2019
Intermittent Claudication - Pipeline by Helixmith Co Ltd, H2 2019
Intermittent Claudication - Pipeline by ID Pharma Co Ltd, H2 2019
Intermittent Claudication - Pipeline by Novartis AG, H2 2019
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc, H2 2019
Intermittent Claudication - Dormant Projects, H2 2019
Intermittent Claudication - Discontinued Products, H2 2019